Clinical Trial Update: Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene [Phase 2]

View source ↗

Summary

Ultevursen is being evaluated in a Phase 2 trial for retinitis pigmentosa caused by USH2A exon 13 mutations, and recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa
• Usher Syndrome Type Ii

Drugs mentioned

• Ultevursen

Snippet

Sponsor: Laboratoires Thea | Conditions: Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Status: RECRUITING